Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps they are taking to ensure haemato-oncology services have the capacity to plan and adopt new innovations in the treatment of blood cancer.

The National Disease Registration Service, through the National Cancer Registration and Analysis Services, collects information on how many people in England have blood cancer, labelled as haematological neoplasms. This data supports service provision and commissioning in the National Health Service, clinical audits, and public health and epidemiological research, all of which contributes to improved outcomes for cancer patients, including blood cancer patients.

The Department is committed to implementing the recommendations of Lord O'Shaughnessy’s review into commercial clinical trials, making sure that the United Kingdom leads the world in clinical trials, and ensuring that innovative, lifesaving treatments are accessible to NHS patients, including those with blood cancer.